Traws Pharma (TRAW) Competitors $4.99 -0.05 (-0.99%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrends TRAW vs. AQST, VERV, SAGE, SIGA, LRMR, PRTC, LXRX, EBS, XERS, and TERNShould you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include Aquestive Therapeutics (AQST), Verve Therapeutics (VERV), Sage Therapeutics (SAGE), SIGA Technologies (SIGA), Larimar Therapeutics (LRMR), PureTech Health (PRTC), Lexicon Pharmaceuticals (LXRX), Emergent BioSolutions (EBS), Xeris Biopharma (XERS), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical preparations" industry. Traws Pharma vs. Aquestive Therapeutics Verve Therapeutics Sage Therapeutics SIGA Technologies Larimar Therapeutics PureTech Health Lexicon Pharmaceuticals Emergent BioSolutions Xeris Biopharma Terns Pharmaceuticals Traws Pharma (NASDAQ:TRAW) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation. Does the MarketBeat Community favor TRAW or AQST? Aquestive Therapeutics received 209 more outperform votes than Traws Pharma when rated by MarketBeat users. CompanyUnderperformOutperformTraws PharmaN/AN/AAquestive TherapeuticsOutperform Votes20967.86% Underperform Votes9932.14% Does the media prefer TRAW or AQST? In the previous week, Aquestive Therapeutics had 4 more articles in the media than Traws Pharma. MarketBeat recorded 4 mentions for Aquestive Therapeutics and 0 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 1.00 beat Aquestive Therapeutics' score of 0.51 indicating that Traws Pharma is being referred to more favorably in the media. Company Overall Sentiment Traws Pharma Positive Aquestive Therapeutics Positive Do insiders and institutionals believe in TRAW or AQST? 7.9% of Traws Pharma shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 16.1% of Traws Pharma shares are owned by company insiders. Comparatively, 7.9% of Aquestive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer TRAW or AQST? Aquestive Therapeutics has a consensus target price of $8.83, indicating a potential upside of 60.02%. Given Aquestive Therapeutics' higher possible upside, analysts clearly believe Aquestive Therapeutics is more favorable than Traws Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AAquestive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Which has stronger earnings & valuation, TRAW or AQST? Aquestive Therapeutics has higher revenue and earnings than Traws Pharma. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTraws Pharma$226K40.35-$18.95M-$138.50-0.04Aquestive Therapeutics$58.36M8.61-$7.87M-$0.35-15.77 Which has more risk and volatility, TRAW or AQST? Traws Pharma has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500. Comparatively, Aquestive Therapeutics has a beta of 2.85, suggesting that its stock price is 185% more volatile than the S&P 500. Is TRAW or AQST more profitable? Aquestive Therapeutics has a net margin of -44.07% compared to Traws Pharma's net margin of -60,641.14%. Aquestive Therapeutics' return on equity of 0.00% beat Traws Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Traws Pharma-60,641.14% -144.95% -633.17% Aquestive Therapeutics -44.07%N/A -28.26% SummaryAquestive Therapeutics beats Traws Pharma on 13 of the 17 factors compared between the two stocks. Ad Porter & CompanyWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Traws Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRAW vs. The Competition Export to ExcelMetricTraws PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.12M$7.02B$5.40B$8.53BDividend YieldN/A7.97%5.15%4.14%P/E Ratio-0.049.53113.7615.14Price / Sales40.35385.111,483.0493.53Price / CashN/A47.3339.7134.04Price / Book0.395.324.665.01Net Income-$18.95M$153.56M$119.06M$225.46M7 Day Performance0.72%0.12%0.79%0.37%1 Month Performance-12.44%15.23%5.65%3.57%1 Year PerformanceN/A41.16%36.80%29.42% Traws Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRAWTraws Pharma1.7007 of 5 stars$4.99-1.0%N/AN/A$9.12M$226,000.00-0.0417Positive NewsGap UpAQSTAquestive Therapeutics1.597 of 5 stars$5.64+2.7%$8.83+56.6%+258.4%$513.46M$58.36M-16.11160Upcoming EarningsNews CoverageVERVVerve Therapeutics2.3276 of 5 stars$6.03+1.5%$26.00+331.2%-49.5%$510.26M$11.76M-2.33110Upcoming EarningsSAGESage Therapeutics4.3341 of 5 stars$8.42-1.4%$13.76+63.5%-69.3%$506.73M$97.24M-1.13690Earnings ReportAnalyst ForecastAnalyst RevisionSIGASIGA Technologies2.7842 of 5 stars$7.03+0.1%N/A+42.5%$501.73M$139.92M6.0140Upcoming EarningsOptions VolumeLRMRLarimar Therapeutics2.8575 of 5 stars$7.86-1.9%$20.43+159.9%+169.7%$501.55MN/A-7.0230Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePRTCPureTech Health2.8842 of 5 stars$20.74+2.8%$45.00+117.0%+15.0%$496.31M$3.33M0.00100Positive NewsLXRXLexicon Pharmaceuticals1.9234 of 5 stars$2.00+7.5%$8.00+300.0%-9.0%$492.45M$3.64M-2.56285Analyst ForecastNews CoverageGap DownEBSEmergent BioSolutions4.3507 of 5 stars$9.27-4.1%$12.00+29.4%+365.8%$485.77M$1.07B-0.821,600Upcoming EarningsShort Interest ↓XERSXeris Biopharma3.804 of 5 stars$3.22-0.3%$4.67+44.9%+72.7%$477.38M$181.41M-7.49290News CoverageTERNTerns Pharmaceuticals4.6147 of 5 stars$6.66+2.3%$15.90+138.7%+32.2%$468.46M$1M-5.0540Analyst ForecastNews Coverage Related Companies and Tools Related Companies Aquestive Therapeutics Competitors Verve Therapeutics Competitors Sage Therapeutics Competitors SIGA Technologies Competitors Larimar Therapeutics Competitors PureTech Health Competitors Lexicon Pharmaceuticals Competitors Emergent BioSolutions Competitors Xeris Biopharma Competitors Terns Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRAW) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
